478 related articles for article (PubMed ID: 30560413)
1. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
Dholaria BR; Bachmeier CA; Locke F
BioDrugs; 2019 Feb; 33(1):45-60. PubMed ID: 30560413
[TBL] [Abstract][Full Text] [Related]
2. [Practical aspects of the application of CAR T cells and management of their toxicities].
Bücklein V; Blumenberg V; Subklewe M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189
[TBL] [Abstract][Full Text] [Related]
3. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
Chou CK; Turtle CJ
Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
[No Abstract] [Full Text] [Related]
4. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
5. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
Freyer CW; Porter DL
J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
[TBL] [Abstract][Full Text] [Related]
6. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
7. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
Porter D; Frey N; Wood PA; Weng Y; Grupp SA
J Hematol Oncol; 2018 Mar; 11(1):35. PubMed ID: 29499750
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
9. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
Ahmad A; Uddin S; Steinhoff M
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486160
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
11. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
[TBL] [Abstract][Full Text] [Related]
12. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
13. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
14. Managing the toxicities of CAR T-cell therapy.
Neelapu SS
Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
16. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
[TBL] [Abstract][Full Text] [Related]
17. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies.
Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME
Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062
[TBL] [Abstract][Full Text] [Related]
18. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
Ruff MW; Siegler EL; Kenderian SS
Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
[TBL] [Abstract][Full Text] [Related]
19. Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
[TBL] [Abstract][Full Text] [Related]
20. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
